This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pfizer, AmSurg: New Targets, Estimates

Also see: Expedia, Citigroup, Target: New Ratings

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGES

Alliance Data (ADS - Get Report) target boosted at RBC. Shares of ADS now seen reaching $96, according to RBC. Company should reach it's near-term earnings targets. Outperform rating.

AmSurg Corp (AMSG - Get Report) price target boosted at Citi to $32.50 from $24. Bullish on acquisition of Dallas based National Surgical Care, Citigroup said. Maintain Buy rating.

Constellation (STZ) estimates, target upped at UBS. STZ estimates were boosted through 2013, UBS said. Company is realizing higher shipments. Buy rating and new $25 price target.

Healthspring (HS) estimates reduced at Goldman through 2013, Goldman Sachs said. Company is realizing a lower Medicare reimbursement. Neutral rating and $46 price target.

Imax (IMAX - Get Report) target raised at Piper. Shares of IMAX now seen reaching $37. Company is expanding its reach across the globe. Overweight rating.

JC Penney (JCP) numbers upped at Piper. JCP estimates were boosted through 2012, Piper Jaffray said. Company is realizing higher sales. Neutral rating and new $32 price target.

Limited Brands (LTD) target boosted at Morgan Stanley. Shares of LTD now seen reaching $41, according to Morgan Stanley. Company is posting double-digit sales growth. Overweight rating.

Priceline.com (PCLN - Get Report) estimates, target raised at Goldman. Shares of PCLN now seen reaching $600, according to Goldman Sachs. Estimates also increased, given expected growth in Europe. Buy rating.

Pepsico (PEP) estimates lowered at Goldman through 2012, Goldman Sachs said. Company is spending more on domestic marketing. Buy rating and $77 price target.

Pfizer (PFE - Get Report) price target raised at Credit Suisse to $23 from $21. Value exists in the case of a Pfizer Animal Health spin-off, Credit Suisse said. Maintain Outperform rating.

Pier 1 Imports (PIR - Get Report) price target higher at Credit Suisse. PIR shares now seen reaching $13, up from $11. Strong comps reinforce solid long-term growth, Credit Suisse said. Maintain Neutral rating.

Seagate Technology (STX - Get Report) numbers increased at Goldman through 2013, Goldman Sachs said. Company is realizing higher margins. Neutral rating and new $16 price target.

Target price target reduced at Goldman to $60, according to Goldman Sachs. Cinoany is seeing weaker sales. Buy rating.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG
PFE $33.46 0.00%
PIR $12.88 0.00%
PCLN $1,264.15 0.00%
STX $56.29 0.00%
ADS $296.66 0.00%

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs